Loading...

Filament Health Corp.

FH.NE•NEO
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.01
CA$-0.00(-33.33%)

Filament Health Corp. (FH.NE) Stock Overview

Explore Filament Health Corp.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.2/100

Key Financials

Market Cap3.9M
P/E Ratio-0.50
EPS (TTM)$-0.02
ROE-2.14%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 Month$0.02
3 Months$0.02
1 Year Target$0.04

FH.NE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Filament Health Corp. (FH.NE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 41.03, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.04.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.50 and a market capitalization of 3.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

41.03RSI (14)
0.00MACD
44.24ADX
Stats data is not available for FH.NEStats details for FH.NE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for FH.NEAnalyst Recommendations details for FH.NE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Filament Health Corp. operates as a natural psychedelic drug discovery and extraction technology company. It propagates psychedelic plants; conducts genetic research; performs extraction procedures; runs in-house trials; and distributes IP and drug candidates to drug developers, researchers, and other licensed parties. The company is headquartered in Vancouver, Canada.

CEO

Benjamin Lightburn

Employees

13

Headquarters

2900 – 550 Burrard Street, Burnaby, BC

Founded

2021

Frequently Asked Questions

;